Back to Search Start Over

Response to trametinib, hydroxychloroquine, and bevacizumab in a young woman with NRAS-mutated metastatic intrahepatic cholangiocarcinoma: a case report

Authors :
Aram A. Musaelyan
Ekaterina M. Anokhina
Alina I. Turdubaeva
Natalia V. Mitiushkina
Anastasia N. Ershova
Anna D. Shestakova
Aigul R. Venina
Evgeny N. Imyanitov
Sergey V. Orlov
Source :
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 3, Pp 780-788 (2024)
Publication Year :
2024
Publisher :
Open Exploration Publishing Inc., 2024.

Abstract

Systemic chemotherapy is the main treatment option for patients with advanced intrahepatic cholangiocarcinoma (iCCA), however, its efficacy is limited. Herein, we report a young patient with NRAS-mutated chemoresistant metastatic iCCA, who received second-line therapy with a combination of trametinib (MEK1/2 inhibitor), hydroxychloroquine (autophagy inhibitor), and bevacizumab (angiogenesis inhibitor). A significant response was achieved during therapy, resulting in a 25% decrease in the size of tumor lesions after 2 months of treatment and an improvement in the patient’s condition. The duration of this response was 4 months, but the patient died 10 months after the initiation of this triple therapy. This case report and the analysis of other available studies warrant further investigations on combined MEK and autophagy inhibition in RAS-mutated tumors.

Details

Language :
English
ISSN :
26923114
Volume :
5
Issue :
3
Database :
Directory of Open Access Journals
Journal :
Exploration of Targeted Anti-tumor Therapy
Publication Type :
Academic Journal
Accession number :
edsdoj.15c6b988128b481890e948ca980a13a8
Document Type :
article
Full Text :
https://doi.org/10.37349/etat.2024.00246